prostanoid

Prostaglandin E1 (Alprostadil) is the naturally occurring prostaglandin E1 (PGE1) which displays a variety of pharmacologic actions. Prostaglandin E1 is a potent vasodilator agent that increases peripheral blood flow, inhibits platelet aggregation, and induces bronchodilation. Used in the treatment of erectile dysfunction, this agent produces corporal smooth muscle relaxation by binding to PGE receptors, resulting in the activation of adenylate cyclase and the subsequent accumulation of 3'5'-cAMP.

Latanoprost acid is a selective agonist of prostanoid receptors and inhibits RANKL-induced osteoclastogenesis and function through the inhibition of c-fos/NFATc1 pathway. Latanoprost acid can be used in studies about lowering pressure inside the eyes.

Bimatoprost acid (17-phenyl trinor PGF2α) is a metabolically stable analog of PGF2α and has a potential antagonistic activity for the FP receptor. It has a relative potency of 756% compared to PGF2α for binding to the FP receptor on ovine luteal cells.

Latanoprost (Xalatan) is a prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect.

Aganepag, a potent Prostanoid EP2 receptor agonist, exhibits remarkable selectivity with an EC50 of 0.19 nM, demonstrating no activity at the EP4 receptor. Its applications are primarily in the fields of wound healing, scar reduction, scar prevention, and the treatment and prevention of wrinkles.

L-902688 is a potent, highly selective and orally active EP4 receptor agonist with a Ki value of 0.38 nM and an EC50 value of 0.6 nM. Its selectivity for the EP4 receptor is more than 4000-fold higher than that for other EP receptors and prostanoid receptors.

EP4 Receptor Antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist, effective for cancer immunotherapy. It inhibits both human and mouse EP4 receptors with IC50 values of 6.1 nM and 16.2 nM, respectively, while displaying minimal activity (IC50s >10 μM) against human EP1, EP2, and EP3 receptors.

Latanoprost lactone diol is an important intermediate compound in the synthesis of Latanoprost. Latanoprost, classified as a prostaglandin F2α analogue, functions as an agonist for the FP prostanoid receptor, resulting in a reduction in intraocular pressure (IOP).

MF498 is a novel and selective E prostanoid receptor 4 (EP4 receptor) antagonist, displayed a strong binding affinity for the EP4 receptor (Ki: 0.7 nM).

Timapiprant sodium inhibits mast cell activation of Th2 lymphocytes and eosinophils. Timapiprant sodium is a potent and selective D prostanoid receptor 2 antagonist. Timapiprant sodium potently displaces [3H] PGD2 from human recombinant DP2 (Ki=13 nM), ra

Vidupiprant (AMG 853) is an effective dual antagonist of CRTH2 and prostanoid D receptor with IC50s of 8 nM and 35 nM in human plasma. Vidupiprant can be used in studies about the treatment of asthma.

QCC-374 is a prostanoid agonist. It potentially for the treatment of pulmonary arterial hypertension.

GW627368 (GW 627368X)X is a novel, potent and selective antagonist of prostanoid EP4 receptor.

Prostaglandin K1 (compound 46) is a structurally modified prostanoid analog with an EC50 and Ki of 2800 nM for the EP1 receptor.

Unoprostone isopropyl, a prostanoid and synthetic docosanoid, is approved for the treatment of ocular hypertension and open-angle glaucoma.

Prostaglandin I2 is an unstable prostaglandin compound that inhibits platelet aggregation and induces vasodilation in the pulmonary vasculature via the "I prostanoid" (IP) receptor. AFP 07, a 7,7-difluoroprostacyclin derivative, serves as a selective and potent agonist for the IP receptor (Ki=0.561 nM). It exhibits weaker affinity for EP receptors, with a Ki value of > 100 nM for EP1-3 and > 10 nM for EP4. The compound 16(R)-AFP 07 free acid is an enantiomer of AFP 07. Its biological properties, particularly those involving IP and EP receptors, are yet to be fully assessed.

CAY10449 is an antagonist of the I prostanoid receptor. It is capable of reversing the decrease in transepithelial electrical resistance (TEER) induced by iloprost. Additionally, CAY10449 can counteract the effects of ONO-1301 in mouse models. This compound is useful for research in asthma and allergic airway inflammation.

SC 51322 is an EP1 prostanoid receptor antagonist.

AH13205 is an agonist of EP2 prostanoid receptor.

Timapiprant (OC000459) is a potent and selective D prostanoid receptor 2 (DP2) antagonist (IC50: 13 nM).

L-644,698 is a selective agonist of human prostanoid DP receptor.

LY 150310, a histamine H1-receptor antagonist, can alter prostanoid concentrations in vitro and in vivo.

MF266-1, a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of osteoarthritis and rheumatoid.

S-5751, a prostanoid DP (DP1) antagonist, is used potentially for the treatment of bronchial asthma.